Bad news and good news in AD, and how to reconcile them

David S. Knopman

doi:10.1038/s41582-018-0131-7

Bad news and good news in AD, and how to reconcile them

David S. Knopman

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Abstract

2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.

Original language	English (US)
Pages (from-to)	61-62
Number of pages	2
Journal	Nature Reviews Neurology
Volume	15
Issue number	2
DOIs	https://doi.org/10.1038/s41582-018-0131-7
State	Published - Feb 1 2019

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1038/s41582-018-0131-7

Cite this

@article{d67842dc6902451096a57ef5b3e97b46,

title = "Bad news and good news in AD, and how to reconcile them",

abstract = "2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.",

author = "Knopman, {David S.}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41582-018-0131-7",

language = "English (US)",

volume = "15",

pages = "61--62",

journal = "Nature Reviews Neurology",

issn = "1759-4758",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Bad news and good news in AD, and how to reconcile them

AU - Knopman, David S.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - 2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.

AB - 2018 saw the failure of several large clinical trials that were based on the premise that reduction of amyloid-β levels is an effective treatment for symptomatic Alzheimer disease. Yet, over the same time period, good news also emerged about the diagnostic value of tau PET imaging.

UR - http://www.scopus.com/inward/record.url?scp=85059779362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059779362&partnerID=8YFLogxK

U2 - 10.1038/s41582-018-0131-7

DO - 10.1038/s41582-018-0131-7

M3 - Comment/debate

C2 - 30622292

AN - SCOPUS:85059779362

SN - 1759-4758

VL - 15

SP - 61

EP - 62

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

IS - 2

ER -

Bad news and good news in AD, and how to reconcile them

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this